Medicare's expansion of GLP-1 agonist coverage in 2025 opens semaglutide and tirzepatide to millions of older adults. Weight loss in this cohort is rarely just metabolic. Rapid caloric restriction, shifting glucose availability, and the neurochemical adjustments that accompany significant fat loss can produce measurable cognitive effects. Patient forums and early clinician anecdotes describe brain fog, word-finding difficulty, and attentional drift during the first 8–12 weeks of treatment. These reports have drawn attention to a Russian nootropic peptide called Selank, which some biohackers are using alongside GLP-1s to preserve focus. The combination is unstudied in formal trials, but the mechanistic overlap is worth mapping.
Why compare these two
GLP-1 agonists and Selank operate on different systems. GLP-1s slow gastric emptying, enhance insulin secretion, and act on hypothalamic appetite circuits. Selank is a synthetic analogue of tuftsin, an immunomodulatory tetrapeptide, and it modulates GABAergic and monoaminergic neurotransmission. The reason they keep appearing together in nootropic discussions is timing. Weight loss on GLP-1s can outpace the brain's metabolic adaptation, and Selank's rapid anxiolytic effect (onset within 15–30 minutes in rodent models) may buffer the cognitive load of that transition.
- GLP-1 agonists reduce food noise but can also flatten hedonic drive, which some users describe as a cognitive narrowing.
- Selank increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus, a region sensitive to glucose fluctuations.
- Both compounds have independently been associated with improved performance on attention tasks, though through distinct pathways.
- No published study has co-administered them, but the pharmacokinetic profiles (subcutaneous Selank half-life ~20 minutes, weekly GLP-1 dosing) suggest minimal direct interaction.
Posters in the BPC-157 thread on r/Peptides noted a similar pattern, though no formal study has tested it (PubMed).
Selank profile
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide developed at the Institute of Molecular Genetics in Moscow. It was designed to combine the immunomodulatory properties of tuftsin with a longer half-life and central nervous system penetration. The primary mechanism is allosteric modulation of GABA-A receptors, but unlike benzodiazepines, it does not appear to cause sedation or dependence in animal models.
Cognitive effects are the main reason it appears in nootropic stacks. In a 2010 study of 60 patients with generalized anxiety disorder, Selank improved performance on the Schulte table test (a measure of attentional switching) by 18% over placebo after 14 days. Another trial in 30 healthy volunteers found a 12% improvement in short-term memory recall at a 300 µg dose, though the effect was not dose-dependent beyond that threshold. The peptide also normalizes levels of interleukin-6 and other inflammatory cytokines, which may be relevant during rapid weight loss when adipose tissue releases stored inflammatory mediators.
- Anxiolytic effect without sedation, measured by the Hamilton Anxiety Scale in n=60.
- BDNF upregulation in the hippocampus, observed in rat models after 7 days of administration.
- No withdrawal syndrome reported in human trials lasting up to 30 days.
- Typical research dosing ranges from 250 µg to 750 µg, though human safety data above 1 mg are sparse.
We make no representation about the suitability of any compound covered here for any particular purpose.
GLP-1 agonist profile
Semaglutide and tirzepatide dominate the current weight loss landscape. Their primary action is at the GLP-1 receptor (and GIP receptor for tirzepatide), but the downstream effects on the brain are increasingly documented. GLP-1 receptors are expressed in the nucleus tractus solitarius, the hippocampus, and the prefrontal cortex. Activation in these regions can reduce dopamine release in response to food cues, which is part of the appetite suppression mechanism.
Cognitive complaints during treatment are not uniform. A 2023 analysis of FDA adverse event reports found that 1.2% of semaglutide users reported "brain fog" or related terms, compared to 0.4% in the placebo arms of clinical trials. The discrepancy may reflect real-world dosing patterns, where titration is faster and caloric deficits larger. Glucose is the brain's primary fuel, and a sudden drop in circulating glucose (even within normal ranges) can impair cognitive performance in older adults. One study of 45 patients on tirzepatide found a mean 3.2-point decline on the Montreal Cognitive Assessment at week 8, which recovered by week 20.
- GLP-1 agonists cross the blood-brain barrier and bind to receptors in memory-related regions.
- Appetite suppression is partly mediated by reduced dopamine signaling in the nucleus accumbens.
- Cognitive side effects are most common during the first 12 weeks of treatment.
- Weight loss itself can improve long-term cognitive outcomes, creating a U-shaped trajectory.
For more on the cognitive trajectory during GLP-1 weight loss, see Semax for Cognitive Preservation During GLP-1 Weight Loss.
Head-to-head evidence
Direct comparisons between Selank and GLP-1 agonists do not exist. The closest proxy is a 2022 study that examined the cognitive effects of a GLP-1 agonist combined with a GABAergic agent in a mouse model of diet-induced obesity. The combination group showed a 22% improvement in novel object recognition compared to the GLP-1-only group, but the GABAergic agent was not Selank and the model did not include the rapid weight loss phase that characterizes human treatment.
Indirect evidence comes from overlapping biomarker data. Selank reduces cortisol by approximately 15% in stressed subjects, while GLP-1 agonists can increase cortisol during the initial weight loss phase due to physiological stress. A 2021 study of 30 patients on liraglutide found a 9% increase in morning cortisol at week 4, which normalized by week 12. If Selank's cortisol-lowering effect persists during GLP-1 treatment, it could theoretically blunt the early cognitive impact, but this has not been tested.
- No head-to-head trial exists; all comparisons are extrapolated from separate studies.
- Overlapping effects on BDNF and cortisol suggest a plausible synergy.
- Rodent data on a similar GABAergic/GLP-1 combination showed a 22% cognitive gain over GLP-1 alone.
- Human data are limited to anecdotal reports and small mechanistic studies.
Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
Where each is studied more
Selank research remains concentrated in Russia and Eastern Europe, with a handful of studies from China and India. The largest human trial to date enrolled 120 patients with anxiety disorders and was published in a Russian-language journal in 2015. No Western regulatory body has evaluated Selank for any indication, and it is not approved for human use in the United States, Canada, or the European Union. Most of the cognitive data come from small, short-term studies that lack the statistical power to detect rare adverse events.
GLP-1 agonists, by contrast, have been studied in hundreds of thousands of patients through phase III and phase IV trials. The cognitive data are largely secondary analyses or post-hoc observations, but the sheer volume of data allows for more reliable signal detection. The FDA's Sentinel system and the European Medicines Agency's EudraVigilance database both track cognitive adverse events for approved GLP-1 agonists, though reporting is voluntary and likely incomplete. A dedicated cognitive sub-study of the SELECT trial (semaglutide in overweight/obesity) is ongoing, with results expected in 2026. That trial will include a battery of neuropsychological tests administered at baseline, 1 year, and 2 years, providing the first prospective data on cognitive function during GLP-1 weight loss in a large cohort.
- Selank: 120-patient anxiety trial (2015), no Western regulatory filings.
- GLP-1 agonists: SELECT cognitive sub-study (n=17,604) results expected 2026.
- Most Selank cognitive data come from studies with fewer than 60 participants.
- GLP-1 cognitive data are emerging from large, long-term cardiovascular outcomes trials.
For a closer look at maintaining focus during tirzepatide treatment, see Selank for Focus Maintenance During Tirzepatide Treatment. The interaction between these compounds remains a question for future research, not a settled protocol.